IMPORTANCE Atrial fibrillation (AF) is the most common arrhythmia affecting 1% of the population. Young individuals with AF have a strong genetic association with the disease, but the mechanisms remain incompletely understood.
R apid progress has been made in defining the genetic architecture 1 of complex diseases such as diabetes, hypertension, atrial fibrillation (AF), and myocardial infarction. A common and efficient approach has been to use genome-wide association studies (GWAS) to identify diseaseassociated loci. 2 Challenges of GWAS include incomplete coverage of the genome, limited ascertainment of rare variation, and difficulties identifying causal genes and variants. A complementary approach to GWAS is to perform exome sequencing in affected individuals to identify loss-offunction (LOF) variants that unequivocally disrupt gene function and directly implicate susceptibility genes as being causally related to disease. For example, a study published in 2016 of 6924 individuals with early-onset myocardial infarction found that individuals with LOF mutations in ANGPTL4 (Ensembl ENSG00000167772) had lower triglyceride levels and a lower risk of coronary heart disease than noncarriers. 3 In 1998 Haissaguerre et al 4 found that AF arose from ectopic electrical foci in the pulmonary veins, an observation that led to the widespread use of catheter ablation procedures to treat paroxysmal and persistent AF. 5 However, AF does not appear to originate from the pulmonary veins in all individuals, and the prevailing mechanisms that sustain AF in individuals remain unclear. The etiology of AF remains incompletely understood. Since young individuals with AF appear to have a strong genetic basis for the disease, large-scale, deep-coverage whole-genome sequencing was performed in patients with early-onset AF.
Methods

Study Populations and Quality Control
Whole-Genome Sequencing The Trans-Omics for Precision Medicine (TOPMed) Program is a National Heart, Lung, and Blood Institute-funded initiative to perform whole-genome sequencing to facilitate genetic discovery in complex human diseases. The first phase of the program included individuals with AF, chronic obstructive pulmonary disease, or asthma, as well as participants from longitudinal studies such as the Framingham Heart Study (FHS) and the Jackson Heart Study. All participants provided written informed consent, and all participating studies obtained ethical approval from their local institutional review boards.
Patients with early-onset AF (cases) were included in this program from 9 sites in the United States (eTable 1 and eAppendix 1 in Supplement 1). Early-onset AF was defined as AF with onset prior to 66 years of age. Case participants were included from the Atherosclerosis Risk in Communities Study, Cleveland Clinic Lone Atrial Fibrillation GeneBank Study, The Heart and Vascular Health Study, FHS, Massachusetts General Hospital Atrial Fibrillation Study, Partners HealthCare Biobank, Women's Genome Health Study, Vanderbilt Atrial Fibrillation Registry, and the Vanderbilt Atrial Fibrillation Ablation Registry. Population-based controls were derived from the remaining studies in phase 1 of this program; as described in eFigure 1 in Supplement 1, participants of genetically determined European ancestry were selected as controls. Control participants from the FHS were excluded if they had a diagnosis of AF. The AF status was unknown in participants from the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease Study (COPDGene), the Cleveland Family Study (CFS), and the Pharmacogenomics of Bronchodilator Response in Minority Children with Asthma Study (GALAII+SAGE).
Replication of a common variant associated with AF was performed using the UK Biobank, an independent dataset composed of individuals aged 40 to 69 years. Participants were recruited in the United Kingdom between 2006 and 2010 and underwent genome-wide genotyping and imputation. Phenotypic data included disease information obtained through self-report, verbal interviews, and linkage to national outpatient, inpatient, and other registries. The present analyses were conducted in unrelated adults of European ancestry. All participants provided written informed consent to participate in research as previously described, 6 and the UK Biobank was approved by the UK Biobank Research Ethics Committee. Use of UK Biobank data was approved by the local Massachusetts General Hospital institutional review board. The ascertainment of AF has been previously described. 7 Rare variant associations between LOF variants in the titin (TTN) (ENSG00000155657) gene and AF were replicated in an independent population from the MyCode Community Health Initiative at Geisinger. This precision health project included individuals with exome sequence data, generated through the DiscovEHR collaboration with Regeneron Genetics Center, linked to electronic health record data with opt-in participant informed consent. 8 The present analysis used data from the participants with completed exome sequencing and available electronic health record data as of October 20, 2017. Sample preparation and exome sequencing were completed per standard Regeneron Genetics Center methodology, as described by Dewey et al.
Early-onset AF was defined based on International Classification of Diseases, Tenth Revision (ICD-10) codes on patient encounters (at least 2 outpatient or 1 inpatient) prior to age 66 years and in the absence of diagnostic codes for myocardial infarction, cardiomyopathy, or heart failure. Control participants were selected from the remaining sequenced population with no encounter coded for AF, heart failure, cardiomyopathy, or myocardial infarction.
Sequencing Methods and Quality Control
Participants were sequenced at the Broad Institute, the Northwest Genomic Center at the University of Washington, and the New York Genome Center. Central quality control and variant calling was performed jointly at the University of Michigan Informatics Resource Center (eAppendix 2 in Supplement 1). Further quality control, focused on sample identity, was performed at the University of Washington Data Coordinating Center. All methods are described on the dbGaP website. 10 
Derivation of the Study Participants
For an overview of the derivation of the study participants and quality control, see eFigure 1 in Supplement 1.F r o m participants who underwent genome sequencing, those who did not provide a suitable consent were excluded from further study. Due to the limited availability of individuals of non-European ancestry with early-onset AF, the study was restricted to individuals of European ancestry to enhance power for genetic analyses. Participants of European ancestry were selected using principal components of genetic ancestry. In brief, common variants that were present in phase 1 participants of this program and the 1000 Genomes Project, 11 who were in low linkage disequilibrium, were selected using PLINK. 12 Principal components were estimated using the smartpca function of Eigenstrat 13 on an unrelated subset of the study participants (ie, beyond 2 estimated degrees of relatedness) identified using kinship coefficients derived from KING. 14 Principal components were then projected onto the related subset. European ancestry participants were selected if the first and second principal components were within 6 standard deviations of the mean of the first and second principal components of European ancestry participants from the 1000 Genomes Project as shown in eFigure 2A in Supplement 1. Principal components were then recomputed using the selected participants of European ancestry. The remaining participants underwent further sample level quality control.
Variant-Level Quality Control
Monomorphic variants, those located in low-complexity regions, 15 or variants with Hardy-Weinberg equilibrium P values of less than 5 × 10 −9 among unrelated control participants, were excluded from the data set.
Participant-Level Quality Control
Among selected participants of European ancestry, duplicate participants between studies were identified based on identity by state using PLINK, 12 and 1 participant for each duplicate pair was excluded (with the exception of known monozygotic twins, who were not exclued). Participants with discordant reported and genetically inferred sex, using chromosome X, were also omitted. Five quality metrics for the sequence data were calculated for detecting outliers: call rate, transition to transversion ratio, number of singletons, heterozygote to homozygote ratio, and single-nucleotide polymorphism (SNP) to indel ratio. Participants with any metric beyond 8 times the standard deviation from the mean were omitted. After excluding individuals who were outliers, monomorphic variants were again tabulated and removed. Additional information regarding participant-level quality control is provided in Table; and in eFigure 3 in Supplement 1. Upon completion of participant-level quality control, a set of individuals were available for genetic analyses (eFigure 1 in Supplement 1). 
Statistical Analysis
For the common variant analyses, the association between a variant and early-onset AF was tested using the score test from logistic mixed-effect models to account for relatedness and assumed an additive genetic model. 16 Models were adjusted for fixed effects of sex and 4 principal components of ancestry associated with early-onset AF. A random effect was used to account for relationships using the empirical kinship matrix. Prior to the common variant analysis, the principal component analysis and the kinship estimation were repeated using the final selected participants. Since the AF status was unknown for control participants from COPDGene, CFS, and GALAII + SAGE studies, age was not adjusted in a regression model. Any variant with minor allele frequency of less than 1% in the overall sample, in case participants alone, or in controls alone, was excluded.
Common variants with a 2-sided score-test P value of less than 5 × 10 −8
, a conventional genome-wide significance threshold, were considered significant. To minimize the probability of reporting spurious associations, significant variants in regions without additional variants, with a P value of less than 1×10 −6 present within a 500-kilobase flanking region, were not reported. For novel variants exceeding the prespecified threshold for genome-wide significance, an in silico replication was performed in the UK Biobank. Among unrelated individuals of European ancestry, an association between genetic variants and early-onset AF, adjusting for age, sex, and principal components, was tested as previously described. 7 Next, a fixed-effects inverse-variance-weighted meta-analysis was performed with results from the whole-genome sequencing discovery analysis and replication analysis in the UK Biobank using METAL. 17 A 2-sided P value of less than .05 with the same direction of effect as the discovery represented evidence of replication for an association. For rare variant analyses, the association between rare variants and early-onset AF was analyzed using logistic regression and adjusted for sex and 4 principal components of ancestry.
18 First, unrelated individuals were selected using a stringent kinship coefficient threshold of 0.022 (Table) . This was necessary because this study has many more related individuals in the control group than in the group with early-onset AF (the case group), which can result in spurious associations for rare variants even when using methods that account for relationships. Analyses of rare coding variants focused on the genes within the 25 known AF GWAS loci, 7 identified in individuals of European ancestry and 1 newly identified AF locus. Each locus was defined as the region bounded by variants with a linkage disequilibrium r 2 of at least 0.3 from the sentinel SNP at each locus. Rare variant analyses were restricted to LOF variants as annotated using SnpEff 4.1, 19 and conservatively defined as nonsense, splice site disrupting, predicted to disrupt transcript reading frame, or large deletions affecting more than 50% of the protein-coding sequence of the transcript or eliminating the first exon. 20 This analysis was motivated by the goal of identifying genes causally related to AF. Of the 84 genes present in the 26 AF susceptibility loci, 11 had a cumulative minor allele count of at least 10 for LOF variants. Therefore, after correcting for multiple testing, a 2-sided P value of less than 4.55 × 10 −3 (0.05/11) was used to indicate evidence of association. For significantly associated genes, the proportion of individuals carrying a variant in the gene was tabulated and 95% CIs were estimated using an exact binomial method. In addition, post hoc association analyses between rare LOF variation in TTN and early-onset AF (see Results) were conducted. Since mutations in TTN have been well described in other cardiomyopathies, 21-27 a post hoc TTN sensitivity analysis restricted to early-onset AF participants (case group) with no evidence of heart failure, cardiomyopathy prior to AF onset, and a documented left ventricular ejection fraction of at least 50% was performed with logistic regression to examine the association between early-onset AF using different age thresholds as the case definition (ie, <66, <50, <40, and <30 years at onset), adjusting for sex and ancestry principal components. For the TTN sensitivity analysis, a fixed-effects inversevariance-weighted meta-analysis was performed between the discovery and replication studies. Analyses were performed using Hail 31 and R version 3.3 statistical software tools.
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Missing Data
The principal components of ancestry for all study participants were estimated from genetic variants, and genetically determined sex was used if the sex of a participant was not available. For the common variant analyses, the software package GENESIS was used to impute missing genotypes to a mean using a minor allele frequency calculated from other participants.
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Results A summary of the participant selection process and the analytic workflow is illustrated in Figure 1 . Whole-genome sequencing was performed in 18 526 individuals in the program. After excluding 2649 individuals without suitable consent, 9475 participants of European ancestry were identified in an initial principal component analysis. The principal component analysis was then repeated among individuals of European ancestry, and the Amish participants were found to constitute a genetically distinct population (eFigure 2B in Supplement 1). Given that AF ascertainment was unavailable in the Amish subset and they comprised a distinct principal component group, 1115 Amish participants were excluded from the study.
Participant-level quality control steps were then performed and the following 620 individuals were excluded from further analyses: 556 participants from FHS with AF onset at older than 65 years of age or with other comorbidities, 32 duplicates, 18 individuals with a sex mismatch, 7 individuals with undetermined genetic sex, 5 outliers from heterozygote to homozygote ratio, 1 outlier from the SNP to indel ratio analyses, and 1 individual with mislabeled case status.
After participant-level quality control, 7740 participants were included in the genetic analyses. The case group participants (2781 with early-onset AF) came from 9 US-based studies in the Atrial Fibrillation Genetics Consortium. 7 The mean age of AF onset in the case group was 48.7 years, and 72.1% (2006) were men (Table) . The remaining 4959 participants of European ancestry were included as controls (eFigure 1 in Supplement 1). For the 7740 in the case group and the control group, the mean depth of sequence coverage was 37.8 fold, and more than 98 million variants were identified. An association test was performed between early-onset AF and the 8 248 975 common variants with minor allele frequency of 1% or greater observed in the sample population in this study. For the common variant analyses, the mean (SD) missing rate of individual variants was 0.04% (0.001). Variants at 6 previously reported AF loci (PITX2, ENSG00000164093; PRRX1, ENSG00000116132; NEURL1, ENSG00000107954; ZFHX3, ENSG00000140836; KCNN3, ENSG00000143603; and SOX5, ENSG00000134532), and 1 recently identified locus (NAV2, ENSG00000166833, P <5×10 −8 ; Figure 2 ; Figure 3 ; eTable 5 in Supplement 1).
The proportion of individuals with early-onset AF who carried a LOF variant in TTN increased in a stepwise fashion with an earlier age of AF onset ( Figure Additional TTN sensitivity analyses were performed by stratifying by heart failure, age, sex, and study sites (eTable 7 in Supplement 1). The TTN LOF variants located in highly expressed exons were associated with early-onset AF in all sensitivity analyses (P < .05)
Among the 40 LOF variants in AF case group participants from the TTN sensitivity analysis, a subset of variants had been previously reported in association with dilated cardiomyopathy or observed in control populations (eFigure 8; eTable 8 in Supplement 1). There was no overlap in the TTN LOF variants observed in early-onset AF and the TTN mutations reported in association with hypertrophic cardiomyopathy, skeletal myopathies or other cardiomyopathies (eFigure 8 in Supplement 1).
The association between LOF variants in TTN and AF persisted (OR, 4.41 [95% CI, 1.86-10.43]; P =7 .34×10 −4 ) after restricting the analysis to include only exons that are highly expressed in cardiac tissue, defined as exons with a percent splicing index of at least 90% (32 LOF variants). 24 The prevalence of early-onset AF case group participants with a TTN LOF variant in a high cardiac-expressed exon was 1.3% (27 LOF variant carriers), in contrast to 0.3% (7 LOF variant carriers) among control group participants. The relation between TTN LOF variants and early-onset AF was validated in an independent data set from the MyCode Community Health Initiative at Geisinger, which The initial sample selection is from the TOPMed program. Because early-onset atrial fibrillation (AF) participants in the case group were ascertained from European ancestry, genetically determined individuals of European ancestry were identified. Although common variants were tested across the entire genome, rare variants were examined in genes at AF candidate loci. Unrelated individuals were defined as those with pairwise relationships greater than fourth-degree relatives. Further post hoc analyses were performed to characterize an association identified in the rare variant analyses. Independent replication populations were from the UK Biobank (common variant analyses [9525 in the case group; 337 021 in the control group]) and the MyCode study (rare variant analyses [1582 in the case group; 41 200 in the control group]).
a Individuals who underwent whole-genome sequening were from the National Heart, Lung, and Blood Institute TOPMed phase I project, which included 9 sites with participants with early-onset AF.
b For cohort descriptions of participants in the case group and the control group, see eTable 1 in Supplement 1. ). In the MyCode participants, LOF variants in TTN were more enriched among those with an earlier age of AF onset, similar to observations in the discovery study (eTable 11 in Supplement 1).
Discussion
Using large-scale, deep coverage whole-genome sequencing, LOF variants in TTN were found to be statistically associated with a diagnosis of early-onset AF. To date, many individuals with early-onset AF in the absence of overt heart disease have been considered to have idiopathic or lone AF. However, results in this study indicate that a subset of patients with early-onset AF may have a genetic basis. Future studies that perform a prospective genetic evaluation of individuals with early-onset AF will be necessary to determine if there is a causal relationship between LOF variants in TTN and earlyonset AF.
TTN is the largest protein in humans and is critical for normal myocardial function. Titin acts as a molecular scaffold for sarcomere assembly and signaling, providing passive stiffness to the sarcomere. Mutations in TTN have pleiotropic effects and have been associated with tibial muscular dystrophy, 22 hypertrophic cardiomyopathy, 23,27 and dilated cardiomyopathy. 21,24-26 One-third of patients develop heart failure within 5 years of AF diagnosis in community-based settings, Loss-of-function (LOF) variants in participants with early-onset atrial fibrillation (AF) (cases; first row) and controls (second row) are plotted relative to their genomic position. If multiple variants are co-localized, the number of unique variants is indicated above. The participants in this figure were derived from the TTN sensitivity analysis and included 2047 with early-onset AF (cases) and 2166
controls. There were 40 LOF variants in TTN among participants with early-onset AF (cases) and 22 LOF variants among control participants. For consistency with prior reports, the TTN domains (Z-disk, I-band, A-band, M-band) are illustrated with red, blue, green, and purple colors. 23 The region indicated in gray is a large final exon present in 1 TTN transcript (Novex-3). 
Research Original Investigation
Association Between Titin Loss-of-Function Variants and Early-Onset Atrial Fibrillation and AF is common after the onset of heart failure. 35 The cooccurrence of TTN LOF variation in AF and also in dilated cardiomyopathy suggests that impaired sarcomere structure or function may be an overlapping pathophysiologic mechanism in at least some participants with early-onset AF (cases).
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In addition, the optimal treatments for TTN mutation carriers with early-onset AF remains unclear as current antiarrhythmic therapies utilized to treat AF target ion channels. Although only a small percentage of patients with AF carried TTN LOF mutations, the study findings support the role for abnormalities in cardiac structural or sarcomeric proteins in the pathogenesis of AF. Further research is necessary to determine whether individuals with TTN LOF variants will respond to conventional AF treatments, including antiarrhythmic therapy or ablation.
There was also an association between early-onset AF and common genetic variants at all previously reported AF loci (P < .05; eTable 3 in Supplement 1). There is a significant association between common variants at the TTN locus and AF in other studies. 7, 34, 36, 37 The direction and effect size of the association observed in the current study is similar to that previously reported, but the differences observed in statistical significance may be a reflection of the sample size. In the common variant analysis, there was an association between individuals with early-onset AF and genetic variants at the NAV2 locus, a finding that was observed in 2 recent meta-analyses for AF. 34,37 The neuron navigator 2 gene encodes the Nav2 protein that was originally identified as an all-trans retinoic acid responsive gene in a neuroblastoma cell line. 38 Knockout of the NAV2 gene in mice results in loss of normal development of the glossopharyngeal and vagal cranial nerves and a blunted baroreceptor response. 39 This finding presents a potential link between early-onset AF and the autonomic nervous system, particularly since modulation of the autonomic nervous system is the focus of a number of ongoing novel therapies for the treatment of AF.
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There were a number of strengths of the current study. First, this study used large-scale whole-genome sequencing data in the analysis of a complex trait and highlights the strengths of using genome sequencing for genetic discovery and identification of potentially causal associations. Although the case and control participants were derived from several source populations, these participants underwent similar methods for genome sequencing, had comparable depths of sequencing coverage, multiple levels of quality control were applied, and the variants were called jointly.
Second, there were detailed analyses of common and rare genetic variation as well as extensive secondary analyses to support the association between TTN LOF variants and earlyonset AF.
Third, the primary findings from the common and rare variant analyses were replicated in independent studies.
Limitations
This study has several limitations. First, the findings should be interpreted in the context of the study design. Due to the observational study design, it is possible that imbalance between case and control participants could lead to residual confounding that could explain some of our findings. However, the association between TTN LOF variants and early-onset AF was robust to sensitivity analyses for heart failure status, sex, age, and study location; the association between TTN LOF variants and early-onset AF was replicated in an independent study. Second, the analyses were restricted to young and middleaged individuals of European ancestry with AF; therefore, the results may not be applicable to other races or older adults.
Third, even with genome sequencing data for 2781 participants with early-onset AF, the power to detect associations with rare variation and particularly rare noncoding variation is limited. Large studies would be needed to provide power to examine the relationship between clinical outcomes related to TTN LOF variation.
Fourth, due to the low frequency of the TTN mutations among AF case participants, the primary implications of the findings may be for understanding the mechanistic basis of AF rather than for clinical testing. Studies directed at determining the utility of screening or diagnostic testing in the participants with the earliest onset of AF, such as those individuals with an age of AF onset younger than 30 or 40 years, will be helpful.
Conclusions
In a case-control study, there was a statistically significant association between an LOF variant in the TTN gene and early-onset AF, with the variant present in a small percentage of participants with early-onset AF (the case group). Further research is necessary to understand whether this is a causal relationship. The percentage of TTN loss-of-function carriers is plotted vs age (years) category. The age categories for atrial fibrillation (AF) cases are not mutually exclusive and are cumulative when moving from a younger to an older age. This figure represents 4163 unrelated participants (controls and participants with early-onset AF [cases]) without evidence of heart failure and a left ventricular ejection fraction of at least 50%. Whiskers around each dot show 95% exact binomial CIs. LOF indicates loss of function.
Association Role of the Funder/Sponsor: For the analysis of the TOPMed project, the funders of the individual study cohorts had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Investigators associated with each study had access to the data, and Drs Choi and Ellinor were responsible for the final decision to submit the manuscript for publication. Cleveland Clinic Lone Atrial Fibrillation GeneBank Study (CCAF) has enrolled patients with lone atrial fibrillation, defined as atrial fibrillation in the absence of significant structural heart disease. Participants were at least 18 years of age with a history of recurring or persistent lone atrial fibrillation, ≤50% coronary artery stenosis in the coronary arteries (if cardiac catheterization done) or with normal stress test results (documentation of normal cardiac catheterization or stress test required if age ≥50 years), and had normal left ventricular ejection fraction (LVEF) 50%. Individuals were excluded if they had heart failure, history of significant valvular disease (>2+ valvular regurgitation, any valvular stenosis), significant coronary artery disease (>50% coronary artery stenosis), prior myocardial infarction, prior percutaneous coronary intervention, or coronary artery bypass graft, or latest LVEF <50%.
The Heart and Vascular Health Study (HVH) is a case-control study of risk factors for development of cardiovascular disease, conducted in the setting of Kaiser Permanente Washington (formerly Group Health Cooperative), a large integrated healthcare system in Washington State, USA. In the AF study, plan members assigned a new ICD-9 code of 427.31 or 427.32 in the inpatient or outpatient setting during 2001-2007 were identified. Incident AF was verified by review of medical records with the requirement that the AF be documented by 12-lead electrocardiogram and clinically recognized by a physician, with no previous evidence of AF in the medical record. The date that AF was clinically recognized was recorded as the index date for each AF case. This analysis included only AF cases 30 to less than 61 years of age at the index date who self-identified as white; no control subjects from the HVH study were included.
Framingham Heart Study (FHS) is a community-based observational cohort initiated in 1948 to prospectively investigate CVD and its risk factors. The Original cohort (n=5,209) received biennial exams. The Original Cohort children (& spouses), termed the Offspring cohort (n=5,214), were recruited in 1971, and have been examined every four to eight years. In FHS, all cardiovascular hospital and outside records were routinely obtained and electrocardiograms were recorded at all FHS examinations; atrial fibrillation cases through 2017 were verified by two FHS cardiologists.
Massachusetts General Hospital (MGH) AF study has enrolled serial patients with early-onset atrial fibrillation referred to the Arrhythmia Service from July 5, 2001 onwards. Atrial fibrillation was documented by electrocardiography. Individuals with structural heart disease as assessed by echocardiography, hyperthyroidism, myocardial infarction, or heart failure were excluded. Each patient underwent a physical examination and standardized interview. All patients were evaluated by 12-lead electrocardiogram, echocardiogram, and laboratory studies. For the TOPMed Program inclusion criteria were individuals with atrial fibrillation onset prior to 66 years of age in the absence of structural heart disease.
Partners HealthCare Biobank is a biorepository of consented patient samples at Partners HealthCare (parent organization of Massachusetts General Hospital and Brigham and Women's Hospital). Aliquots of DNA, plasma, and serum are linked to electronic medical record data and are available to investigators for use. Cases with earlyonset AF were identified using a validated electronic medical record search algorithm that has been previously described. 1 Briefly, the algorithm is based on diagnostic codes, procedure codes, electrocardiographic information, and medications. The charts of individuals with an electronic medical record indicator of white race, and with an Samples undergo fragmentation by means of acoustic shearing using Covaris focused-ultrasonicator, targeting 385 bp fragments. Following fragmentation, additional size selection is performed using a SPRI cleanup. Library preparation is performed using a commercially available kit provided by KAPA Biosystems (product KK8202) with palindromic forked adapters with unique 8 base index sequences embedded within the adapter (purchased from IDT). Following sample preparation, libraries are quantified using quantitative PCR (kit purchased from KAPA biosystems) with probes specific to the ends of the adapters. This assay is automated using Agilent's Bravo liquid handling platform. Based on qPCR quantification, libraries are normalized to 1.7 nM. Samples are then pooled into 24-plexes and the pools are once again qPCRed. Samples are then combined with HiSeq X Cluster Amp Mix 1,2 and 3 into single wells on a strip tube using the Hamilton Starlet Liquid Handling system.
As described in the library construction process, 96 samples on a plate are processed together through library construction. A set of 24 barcodes is used to index the samples. Barcoding allows pooling of samples prior to loading on sequencers and mitigates lane-lane effects at a single sample level. The plate is broken up into 4 pools of 24-samples each. The four pools are taken as columns on the plate (e.g., columns 1-3; 4-6; 7-9; 10-12). From this format (and given the current yields of a HiSeqX) the 4 pools are spread over 3 flowcells (24 lanes). Cluster amplification of the templates was performed according to the manufacturer's protocol (Illumina) using the Illumina cBot. Flowcells were sequenced on Hi Seq X with sequencing software HiSeq Control Software (HCS) version 3.3.76, then analyzed using RTA2 (Real Time Analysis).
For TOPMed phase 1 data the following versions were used for aggregation, and alignment to hg19_decoy reference: picard (latest version available at the time of the analysis), GATK (3.1-144-g00f68a3) and BwaMem (0.7.7-r441).
A sample is considered sequence complete when the mean coverage is >= 30x. Two QC metrics that are reviewed along with the coverage are the sample Fingerprint LOD score (score which estimates the probability that the data is from a given individual) and % contamination. At aggregation, we do an all-by-all comparison of the read group data and estimate the likelihood that each pair of read groups is from the same individual. If any pair has a LOD score < -20.00, the aggregation does not proceed and is investigated. FP LOD >= 3 is considered passing concordance with the sequence data (ideally we see LOD >10). A sample will have an LOD of 0 when the sample failed to have a passing fingerprint. Fluidigm fingerprint is repeated once if failed. Read groups with fingerprints < -3.00 are blacklisted from the aggregation. If the sample does not meet coverage, it will be topped off for additional coverage. If a large % of read groups are blacklisted, it will be investigated as a potential sample swap. In terms of contamination, a sample is considered passing if the contamination is less than 5%. In general, the bulk of the samples have less than 1% contamination.
At New York Genome Center, genomic DNA samples were submitted in NYGC-provided 2D barcoded matrix rack tubes. Sample randomization was performed at investigator lab prior to sample submission. Upon receipt, the matrix racks were inspected for damage and scanned using a VolumeCheck instrument (BioMicroLab), and tube barcode and metadata from the sample manifest uploaded to NYGC LIMS. Genomic DNA was quantified using the Quant-iT PicoGreen dsDNA assay (Life Technologies) on a Spectramax fluorometer, and the integrity was ascertained on a Fragment Analyzer (Advanced Analytical). After sample quantification, a separate aliquot (100ng) was removed for SNP array genotyping with the HumanCoreExome-24 array (Illumina). Array genotypes were used to estimate sample contamination (using VerifyIDintensity), for sample fingerprinting, and for downstream quality control of sequencing data. Investigator was notified of samples that failed QC for total mass, degradation or contamination, and replacement samples were submitted.
Sequencing libraries were prepared using the TruSeq PCR-free DNA HT Library Preparation Kit (Illumina) with 500 ng DNA input, following manufacturer's protocol with minor modifications to account for automation. Briefly, genomic DNA was sheared using the Covaris LE220 sonicator to a target size of 450 bp (t:78; Duty:15; Supplemental Materials -Titin loss of function variants in early-onset AF © 2018 American Medical Association. All rights reserved.
PIP:450; 200 cycles), followed by end-repair and bead based size selection of fragmented molecules. The selected fragments were A-tailed, and sequence adaptors ligated onto the fragments, followed by two bead clean-ups of the libraries. These steps were carried out on the Caliper SciClone NGSx workstation (Perkin Elmer). Final libraries are evaluated for size distribution on the Fragment Analyzer and quantified by qPCR with adaptor specific primers (Kapa Biosystems).
Final libraries were multiplexed for 8 samples per sequencing lane, with each sample pool sequenced across 8 flow cell lanes. 1% PhiX control was spiked into each library pool. The library pools were quantified by qPCR, loaded on the to HiSeq X patterned flow cells and clustered on an Illumina cBot following manufacturer's protocol. Flow cells were sequenced on the Illumina HiSeq X with 2x150bp reads, using V2 sequencing chemistry, and Illumina HiSeq Control Software v3.1.26.
Demultiplexing of sequencing data was performed with bcl2fastq2 v2.16.0.10, and sequencing data was aligned to human reference build 37 (hs37d5 with decoy) using BWA-MEM v0.7.8. Data was further processed using the GATK best-practices v3.2-2 pipeline, with duplicate marking using Picard tools v1.83, realignment around indels, and base quality recalibration. Individual sample BAM files were squeezed using Bamutil v1.0.9 with default parameters --removing OQ's, retaining duplicate marking and binning quality scores (binMid) --and transferred to the IRC using Globus. Individual sample SNV and indel calls were generated using GATK haplotype caller and joint genotyping was performed across all the NYGC phase 1 samples.
Prior to release of BAM files to IRC, we ensured that mean genome coverage was >=30x, when aligning to the ~2.86Gb sex specific mappable genome, and that uniformity of coverage was acceptable (>90% of genome covered >20x). Sample identity and sequencing data quality was confirmed by concordance to SNP array genotypes. Sample contamination was estimated with VerifyBAMId v1.1.0 (threshold <3%). Gender was determined from X-and Ychromosome coverage and checked against submitter information. Further QC included review of alignment rates, duplicate rates, and insert size distribution. Metrics used for review of SNV and indel calls included: the total number of variants called, the ratio of novel to known variants, and the Transition to Transversion ratios, and the ratio of heterozygous to homozygous variant calls.
The Northwest Genomics Center centralizes all receipt, tracking, and quality control/assurance of DNA samples in a Laboratory Information Management System. Samples are assigned unique barcode tracking numbers and have a detailed sample manifest (i.e., identification number/code, sex, DNA concentration, barcode, extraction method). Initial QC entails DNA quantification, sex typing, and molecular "fingerprinting" using a high frequency, cosmopolitan genotyping assay. This 'fingerprint' is used to identify potential sample handling errors and provides a unique genetic ID for each sample, which eliminates the possibility of sample assignment errors. In addition, we spot check ~8% of the samples per batch on an agarose gel to check for high molecular weight DNA, if DNA degradation is detected all samples are checked. Samples are failed if: (1) the total amount, concentration, or integrity of DNA is too low; (2) the fingerprint assay produces poor genotype data or (3) sex-typing is inconsistent with the sample manifest. Barcoded plates were shipped to Macrogen for library construction and sequencing.
Libraries were constructed with a minimum of 0.4ug gDNA and are prepared in Covaris 96 microTUBE plates and sheared through a Covaris LE220 focused ultrasonicator targeting 350 bp inserts. The resulting sheared DNA is selectively purified using sample purification beads to make the precise length of insert; End-repair (repaired to blunt end), A-tailing (A-base is added to 3'end), and ligation (Y-shaped adapter is used which includes a barcode) are performed as directed by TruSeq PCR-free Kit (Illumina, cat# FC-121-3003) protocols. A second Bead cleanup is performed after ligation to remove any residual reagents and adapter dimers. To verify the size of adapter-ligated fragments, we validate the template size distribution by running on a 2200 TapeStation (Agilent, Catalog # G2964AA) using a TapeStation DNA Screen Tape (Agilent, Catalog 5067-5588). The final libraries are quantified by qPCR assay using KAPA library quantification kit (cat.# KK4808 and KK4953) on a Light Cycler 480 instrument(Roche, cat# 05015278001).
Eight normalized and indexed libraries were then pooled together and denatured before cluster generation on a cBot. The 8-plex pools were loaded on eight lanes of a flow cell and sequenced on a HiSeqX using illumina's HiSeq X ten reagents kit (V2.5, cat# FC-501-2521). For cluster generation, every step is controlled by cBot. When cluster generation is complete, the clustered patterned flow cells are then sequenced with sequencing software HCS (HiSeq Control Software). The runs are monitored for %Q30 bases using the SAV (Sequencing Analysis Viewer). Using RTA 2 (Real Time Analysis 2) the BCLs (base calls) were de-multiplexed into individual FASTQs per sample using illumina package bcl2fastq v2.15.0 and transferred from Macrogen to NWGC for alignment, merging, variant calling and sequencing QC.
Our processing pipeline consists of aligning FASTQ files to a human reference (hs37d5) using BWA-MEM (Burrows-Wheeler Aligner; v0. (1) "duplicate removal" is performed, (i.e., the removal of reads with duplicate start positions; Picard MarkDuplicates; v1.111) (2) indel realignment is performed (GATK IndelRealigner; v3.2) resulting in improved base placement and lower false variant calls and (3) base qualities are recalibrated (GATK BaseRecalibrator; v3.2). Sample BAM files were "squeezed" using Bamutil with default parameters and checksummed before being transferred to the IRC.
All sequence data undergo a QC protocol before they are released to the TOPMed IRC for further processing. For whole genomes, this includes an assessment of: (1) mean coverage; (2) fraction of genome covered greater than 10x; (3) duplicate rate; (4) mean insert size; (5) contamination ratio; (6) mean Q20 base coverage; (7) Transition/Transversion ratio (Ti/Tv); (8) fingerprint concordance > 99%; and (9) sample homozygosity and heterozygosity. All QC metrics for both single-lane and merged data are reviewed by a sequence data analyst to identify data deviations from known or historical norms. Lanes/samples that fail QC are flagged in the system and can be re-queued for library prep (< 1% failure) or further sequencing (< 2% failure), depending upon the QC issue. 
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None of the funding agencies had any role in the study design, data collection or analysis, interpretation of the data, writing of the manuscript, or in the decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, And Blood Institute or the National Institutes of Health. eFigure 3 illustrates quality control metrics after we cleaned the data set. Panels A-E show call rate, heterozygote homozygotes ratio, transition transversion ratio, SNP INDEL ratio, and the number variants with allele count = 1. These panels present a distribution of quality control metrics for all participants and by each study using a boxplot. Panel F presents the total number of samples and sample sizes by each study after quality control. E   0 5000  15000  25000  0 5000  15000  25000  0 5000  15000  25000  0 5000  15000  25000  0 5000  15000  25000  0 5000  15000  25000  0 5000  15000  25000  0 5000  15000  25000  0 5000  15000  25000  0 5000  15000  25000  0 5000  15000  25000  0 5000  15000 Loss of function variants in early-onset atrial fibrillation cases (first row) and controls (second row) are plotted relative to their genomic position. The sample includes in this figure arose from the rare variant analyses and included 2,752 early-onset atrial fibrillation cases and 2,166 controls. There were 64 loss of function variants (LOF) in TTN among the early-onset AF cases and 22 LOF variants in the controls. Variants found in cases with heart failure or left ventricular ejection fractions <50% were colored in orange. For consistency with prior reports, the TTN domains (Z-disk, I-band, A-band, Mband) are illustrated with red, blue, green, and purple colors, respectively 3 . The region indicated in grey is a large, final exon present in one TTN transcript (Novex-3). At the bottom is an overview of the TTN transcripts in which each line indicates an exon. The Meta transcript is a curated summary of the major exons for TTN as described on the Cardiodb website (www.cardiodb.org). The N2BA and N2B transcripts are principal cardiac long and short isoforms of titin, respectively. N2A is expressed in skeletal muscle. Novex-1 (Nvx1) and Novex-2 (Nvx2) are similar to N2B but contains one additional exon. Novex-3 (Nvx3) is smaller isoform with a large alternative final exon. Abbreviation: LOF, loss of function At the top, the TTN loss of function variants in unrelated, early-onset atrial fibrillation cases and controls are plotted relative to their genomic position. In the second section, the TTN variants reported in dilated cardiomyopathy cases and controls from the Cardiodb website (www.cardiodb.org) are illustrated 3 . The third section, includes pathogenic TTN variants from the ClinVar database 2 . From the ClinVar data, separate variants are indicated for dilated cardiomyopathy, skeletal myopathies, other cardiomyopathies, and hypertrophic cardiomyopathy. Any variant in common among early onset AF patients, dilated cardiomyopathy cases and/or controls are colored in red. For consistency with prior reports, the TTN domains (Z-disk, I-band, A-band, M-band) are illustrated with red, blue, green, and purple colors, respectively 3 . The region indicated in grey is a large, final exon present in one TTN transcript (Novex-3). At the bottom is an overview of the TTN transcripts in which each line indicates an exon. The Meta transcript is a curated summary of the major exons for TTN as described on the Cardiodb website (www.cardiodb.org) 3 . The N2BA and N2B transcripts are principal cardiac long and short isoforms of titin, respectively. N2A is expressed in skeletal muscle. Novex-1 (Nvx1) and Novex-2 (Nvx2) are similar to N2B but contains one additional exon. Novex-3 (Nvx3) is smaller isoform with a large alternative final exon.
Abbreviations: AF, atrial fibrillation; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; CMP, cardiomyopathies. The most significant variant at each genetic locus is listed. Abbreviations: Chr, chromosome; OR, odds ratio; CI, confidence interval
